# Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery

> **NCT03384238** · PHASE1,PHASE2 · RECRUITING · sponsor: **George Poultsides** · enrollment: 27 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **PROCEDURE:** Fluorescence Imaging
- **BIOLOGICAL:** Panitumumab
- **DRUG:** Panitumumab-IRDye800

## Key facts

- **NCT ID:** NCT03384238
- **Lead sponsor:** George Poultsides
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-02-07
- **Primary completion:** 2027-03
- **Final completion:** 2027-09
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03384238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03384238, "Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03384238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*